Literature DB >> 14718429

Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea.

David A Calhoun1, Mari K Nishizaka, Mohammad A Zaman, Susan M Harding.   

Abstract

OBJECTIVE: The severity of obstructive sleep apnea (OSA) correlates with the difficulty of controlling BP. The mechanism, however, by which sleep apnea contributes to the development of resistant hypertension remains obscure. Having observed a high prevalence of OSA among hypertensive subjects with primary hyperaldosteronism, we hypothesized a possible association between sleep apnea and aldosterone excretion.
DESIGN: In consecutive subjects referred to a university clinic for resistant hypertension, we prospectively determined plasma renin activity (PRA), plasma aldosterone concentration (PAC), and 24-h urinary aldosterone excretion during high dietary salt ingestion. In addition, all subjects completed the Berlin Questionnaire, a survey designed to identify subjects at risk of having sleep apnea. Primary hyperaldosteronism (PA) was defined as a PRA < 1.0 ng/mL/h and 24-h urinary aldosterone excretion > 12 micro g during high urinary sodium excretion (> 200 mEq/24 h).
RESULTS: Of the 114 subjects evaluated, 72 subjects had a high probability and 42 subjects had a low probability of having sleep apnea based on their responses to the Berlin Questionnaire. Subjects at high risk for sleep apnea were almost two times more likely to have PA diagnosed (36 vs 19%, p < 0.05), tended to have lower PRA (1.2 +/- 1.8 ng/mL/h vs 1.9 +/- 4.1 ng/mL/h), and had significantly greater 24-h urinary aldosterone excretion (13.6 +/- 9.6 micro g vs 9.8 +/- 7.6 micro g, p < 0.05) compared to subjects at low risk of sleep apnea.
CONCLUSION: These data provide evidence of increased aldosterone excretion in subjects with resistant hypertension and symptoms of sleep apnea. While the causality of this association is unknown, it is hypothesized that sleep apnea contributes to the development of resistant hypertension by stimulating aldosterone excretion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718429     DOI: 10.1378/chest.125.1.112

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  77 in total

1.  Sleep and hypertension.

Authors:  David A Calhoun; Susan M Harding
Journal:  Chest       Date:  2010-08       Impact factor: 9.410

Review 2.  Obstructive sleep apnea and hypertension.

Authors:  David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

Review 3.  Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management.

Authors:  Stephen K Williams; Joseph Ravenell; Girardin Jean-Louis; Ferdinand Zizi; James A Underberg; Samy I McFarlane; Gbenga Ogedegbe
Journal:  Curr Diab Rep       Date:  2011-02       Impact factor: 4.810

4.  Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.

Authors:  Carolina C Gonzaga; Krishna K Gaddam; Mustafa I Ahmed; Eduardo Pimenta; S Justin Thomas; Susan M Harding; Suzanne Oparil; Stacey S Cofield; David A Calhoun
Journal:  J Clin Sleep Med       Date:  2010-08-15       Impact factor: 4.062

Review 5.  Treatment of resistant hypertension.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

6.  Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease.

Authors:  Harminder Singh; Richard Pollock; Julia Uhanova; Meir Kryger; Kim Hawkins; Gerald Y Minuk
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

7.  Obstructive sleep apnea and aldosterone.

Authors:  Anna Svatikova; Lyle J Olson; Robert Wolk; Bradley G Phillips; Taro Adachi; Gary L Schwartz; Virend K Somers
Journal:  Sleep       Date:  2009-12       Impact factor: 5.849

Review 8.  Supine fluid redistribution: should we consider this as an important risk factor for obstructive sleep apnea?

Authors:  Aibek E Mirrakhimov
Journal:  Sleep Breath       Date:  2012-08-08       Impact factor: 2.816

Review 9.  Obstructive sleep apnea, hypertension and cardiovascular diseases.

Authors:  C Gonzaga; A Bertolami; M Bertolami; C Amodeo; D Calhoun
Journal:  J Hum Hypertens       Date:  2015-03-12       Impact factor: 3.012

Review 10.  Primary Aldosteronism: Practical Approach to Diagnosis and Management.

Authors:  James Brian Byrd; Adina F Turcu; Richard J Auchus
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.